Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach

References

• Lakhani SR, Manek S, Penault-Llorca F, et al Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10: 2473–2481.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568–2581.
   PubMed Web of Science ®Google Scholar
• Janatova M, Zikan M, Dundr P, Matous B, Pohlreich P. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Hum Mutat 2005; 25: 319.
   Web of Science ®Google Scholar
• Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39: 857–865.
   PubMed Web of Science ®Google Scholar
• Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 166–171.
   Google Scholar
• Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987.
   Google Scholar
• Tavassoli FA, Devilee P. WHO Classification of Tumours; Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
   Google Scholar
• Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7–15.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118–145.
   PubMed Web of Science ®Google Scholar
• Armes JE, Trute L, White D, et al Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011–2017.
   Google Scholar
• Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002; 117: 944–951.
   PubMed Web of Science ®Google Scholar
• O'Neill CJ, Deavers MT, Malpica A, Foster H, McGluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER–2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol 2005; 29: 1034–1041.
   PubMed Web of Science ®Google Scholar
• Tornos C, Soslow R, Chen S, et al Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005; 29: 1482–1489.
   PubMed Web of Science ®Google Scholar
• Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141–161.
   PubMed Web of Science ®Google Scholar
• Schorge JO, Miller YB, Qi LJ, et al Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000; 76: 369–372.
   Google Scholar
• Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158–163.
   PubMed Web of Science ®Google Scholar
• Andikyan V, Taylor HS. WT1 represses HOX gene expression in the regulation of gynecologic tumor histologic type. J Cell Mol Med 2009; 13: 4522–4531.
   Google Scholar
• Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47: 317–322.
   PubMedGoogle Scholar
• Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 2009; 19: 620–627.
   PubMedGoogle Scholar
• Burges A, Bruning A, Dannenmann C, et al Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2009; 281: 511–517.
   Google Scholar
• Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 2009; 115: 401–406.
   Google Scholar
• Cho EY, Choi YL, Chae SW, Sohn JH, Ahn GH. Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms. Int J Gynecol Cancer 2006; 16: 1000–1006.
   Google Scholar
• Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999; 96: 5722–5727.
   PubMed Web of Science ®Google Scholar
• Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553–560.
   PubMed Web of Science ®Google Scholar
• Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007; 31: 1139–1148.
   PubMed Web of Science ®Google Scholar
• Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006; 19: 34–48.
   PubMed Web of Science ®Google Scholar
• Armes JE, Lourie R, de Silva M, et al Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005; 24: 363–368.
   PubMed Web of Science ®Google Scholar
• O'Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007; 50: 773–779.
   Google Scholar
• Subhawong AP, Subhawong T, Nassar H, et al Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33: 163–175.
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10: R75.
   PubMed Web of Science ®Google Scholar